Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €21.58 EUR
Change Today -0.82 / -3.67%
Volume 3.0K
As of 3:09 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

exact sciences corp (EXK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - €25.19
52 Week Low
05/8/14 - €7.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXACT SCIENCES CORP (EXK)

exact sciences corp (EXK) Related Bloomberg News

View More Bloomberg News

exact sciences corp (EXK) Related Businessweek News

No Related Businessweek News Found

exact sciences corp (EXK) Details

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company’s stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with MAYO Foundation for Medical Education and Research for developing tests to detect other gastrointestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

236 Employees
Last Reported Date: 02/27/15
Founded in 1995

exact sciences corp (EXK) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $738.5K
Principal Financial Officer and Senior Vice P...
Total Annual Compensation: $84.6K
Chief Operating Officer, Senior Vice Presiden...
Total Annual Compensation: $508.3K
Chief Science Officer and Senior Vice Preside...
Total Annual Compensation: $474.3K
Compensation as of Fiscal Year 2013.

exact sciences corp (EXK) Key Developments

Exact Sciences Corporation Announces Co-Promotion Agreement with Ironwood Pharmaceuticals

Exact Sciences Corp. and Ironwood Pharmaceuticals Inc. announced an agreement to co-promote the company's Cologuard, a noninvasive stool DNA screening test for colorectal cancer. The agreement provides for the near-term expansion of Cologuard promotional efforts through the use of Ironwood's clinical sales specialists to more than double the number of physicians reached in the US. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension. Ironwood's clinical sales specialists are expected to begin Cologuard promotional efforts in the second quarter of 2015, educating health care practitioners to whom they currently detail LINZESS (linaclotide). LINZESS is the first and only approved therapy in a class of drugs that works differently to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. The agreement augments the company's 140 sales representatives with Ironwood's team of approximately 160 sales representatives. Under the terms of the deal, Ironwood will be compensated from the net sales generated from the physicians on whom they call. LINZESS will remain the first-position product for the Ironwood sales team. The company will maintain responsibility for all other aspects of commercialization of Cologuard. The companies will also collaborate on medical education initiatives to support more in-depth understanding of Cologuard and the importance of colorectal cancer screening.

Exact Sciences Corp. Announces Aetna Medicare Advantage to Cover Cologuard

Exact Sciences Corp. announced that Aetna will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1, 2015. Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be available to Aetna’s Medicare Advantage members through their physician without a co-payment or co-insurance.

Exact Sciences Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Exact Sciences Corporation announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported laboratory service revenue of $1,504,000. Loss from operations was $32,583,000 compared to $12,266,000 a year ago. Net loss was $32,444,000 or $0.38 per basic and diluted share compared to $12,186,000 or $0.17 per basic and diluted share a year ago. For the year, the company reported laboratory service revenue of $1,504,000. Loss from operations was $100,539,000 compared to $46,761,000 a year ago. Net loss was $100,048,000 or $1.25 per basic and diluted share compared to $46,514,000 or $0.69 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXK:GR €21.58 EUR -0.82

EXK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curis Inc $2.79 USD +0.02
Delcath Systems Inc $1.03 USD -0.03
MELA Sciences Inc $1.60 USD -0.10
Navidea Biopharmaceuticals Inc $1.48 USD -0.07
ZIOPHARM Oncology Inc $11.92 USD -0.035
View Industry Companies

Industry Analysis


Industry Average

Valuation EXK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,125.9x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,018.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXACT SCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at